Ipilimumab in the treatment of melanoma

Bibliography

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
   PubMed Web of Science ®Google Scholar
• Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009;229:12-26
   PubMed Web of Science ®Google Scholar
• Seetharamu N, Ott PA, Pavlick AC. Novel therapeutics for melanoma. Expert Rev Anticancer Ther 2009;9:839-49
   PubMed Web of Science ®Google Scholar
• Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 2012;65:9-22
   Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64
   PubMed Web of Science ®Google Scholar
• Bristol-Meyers Squibb. Product Information–Yervoy™. Edited by; 2011. Available from: www.yervoy.com
   Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712-17
   PubMed Web of Science ®Google Scholar
• O'Day SJ, Maio M, Chiarion-Sileni V, Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;21:1712-17
   PubMed Web of Science ®Google Scholar
• Weber JS, O'Day S, Urba W, Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950-6
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372-7
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005;12:1005-16
   PubMed Web of Science ®Google Scholar
• Hersh EM, O'Day SJ, Powderly J, A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011;29:489-98
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Hamid O, Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9
   PubMedGoogle Scholar
• Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guideline–Melanoma. V3.2012. Available from: www.nccn.org [Access 01/10/2012]
   Google Scholar
• Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011;9:277-86
   PubMed Web of Science ®Google Scholar
• Lin R, Yellin MJ, Lowy I, An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 2008;26(15s):abstract 9063
   Google Scholar
• Boasberg P, Hamid O, O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 2010;37:440-9
   PubMed Web of Science ®Google Scholar
• Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40
   PubMed Web of Science ®Google Scholar
• Weber J, Thompson JA, Hamid O, A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8
   PubMed Web of Science ®Google Scholar
• O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:2614-27
   PubMed Web of Science ®Google Scholar
• Carpenter KJ, Murtagh RD, Lilienfeld H, Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 2009;30:1751-3
   PubMed Web of Science ®Google Scholar
• Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13:29-38
   PubMed Web of Science ®Google Scholar
• Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 2011;197:W992-W1000
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
   PubMed Web of Science ®Google Scholar
• Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res 2009;15:7116-18
   PubMed Web of Science ®Google Scholar
• Hoos A, Britten CM, Huber C, O'Donnell-Tormey J. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 2011;29:867-70
   PubMed Web of Science ®Google Scholar
• Lawrence DP, Hamid O, McDermott DF, Phase II Trial of Ipilimumab Monotherapy in Melanoma Patients with Brain Metastases. J Clin Oncol 2010;15S:abstract 8523
   Google Scholar
• Margolin KA, Di Giacomo AM, Maio M. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Semin Oncol 2010;37:468-72
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Testori A, Maio M, Robert C. Anti-CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol 2010;37:455-9
   PubMed Web of Science ®Google Scholar
• Hwu WJ. Targeted therapy for metastatic melanoma: from bench to bedside. HemeOnc Today 2010;10(6):5-8
   Google Scholar
• Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 2011;84:409-21
   PubMedGoogle Scholar
• Vonderheide RH, Flaherty KT, Khalil M, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876-83
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Furman RR, Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4371-7
   PubMed Web of Science ®Google Scholar